Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CRBP

Corbus Pharmaceuticals Holdings Inc

9.08

Jul 27 • 3:59 PM ET -0.09 (-0.98%)

9.08

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: KPTI CAMP CNTX ELTX ENLV RNA TNXP UNCY OABI TENX

| Held by: VTI IWM VXF IWN VTWO FESM DFAS IWC DFMC AVSC

Scroll to Statements

Index	RUT
Market Cap	168.23M
Enterprise Value	30.84M
Income	-84.53M
Sales	0.00M
Book/sh	7.12
Cash/sh	7.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	36
IPO	Oct 27, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.27
P/C	1.21
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.92
Current Ratio	7.92
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-5.81
EPS next Y	-5.15
EPS next Q	-1.26
EPS this Y	21.34%
EPS next Y	-10.99%
EPS next 5Y	2.38%
EPS past 3/5Y	16.56% 32.70%
Sales past 3/5Y	- -
EPS Y/Y TTM	-37.60%
Sales Y/Y TTM	-
EPS Q/Q	11.75%
Sales Q/Q	-
Earnings	May 12 BMO
EPS/Sales Surpr.	-0.78% -

Insider Own	10.29%
Insider Trans	-1.39%
Inst Own	59.52%
Inst Trans	-1.74%
ROA	-59.44%
ROE	-66.70%
ROIC	-66.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.83%
SMA50	3.01%
SMA200	-8.52%
Trades

Shs Outstand	17.74M
Shs Float	16.62M
Short Float	12.61%
Short Ratio	4.21
Short Interest	2.10M
52W High	20.56 -55.84%
52W Low	7.12 27.53%
Volatility	5.11% 5.35%
ATR (14)	0.51
RSI (14)	51.61
Beta	2.59
Rel Volume	0.73
Avg Volume	498.14K
Volume	363,251

Perf Week	2.14%
Perf Month	10.06%
Perf Quarter	-9.74%
Perf Half Y	4.01%
Perf YTD	11.55%
Perf Year	-1.94%
Perf 3Y	41.65%
Perf 5Y	-78.23%
Perf 10Y	-89.19%
Recom	1.00
Target Price	35.30
Prev Close	9.17
Price	9.08
Change	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-26	Initiated	Guggenheim	Buy	$45
Jul-30-25	Resumed	B. Riley Securities	Buy	$28
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform	$85
Jul-22-24	Resumed	H.C. Wainwright	Buy	$80
Jun-26-24	Initiated	B. Riley Securities	Buy	$85
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38

Show Previous Ratings

Jul-06-26 08:00AM	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer (GlobeNewswire)
May-26-26 07:00AM	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers (GlobeNewswire) -30.31%
May-21-26 08:00AM	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call (GlobeNewswire) +18.29%
May-14-26 08:00AM	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors (GlobeNewswire)
May-13-26 07:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.30%
08:06AM	Loading…
May-12-26 08:06AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
08:00AM	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-26 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 (GlobeNewswire)
Apr-29-26 09:42AM	Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls (The Fly)
Apr-22-26 08:00AM	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 (GlobeNewswire)
Apr-14-26 08:00AM	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity (GlobeNewswire)
Apr-07-26 08:00AM	Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer (GlobeNewswire)
Mar-18-26 08:00AM	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit (GlobeNewswire) -6.02%
Mar-09-26 07:48AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +19.23%
07:30AM	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
03:08AM	Loading…
Feb-26-26 03:08AM	Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead (MarketBeat) +6.18%
Feb-12-26 08:00AM	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire)
Jan-05-26 07:30AM	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 11:16AM	2 Pharma Stocks Pop on Strong Obesity Drug Trial Results (Schaeffer's Research) -5.65%
07:00AM	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (GlobeNewswire)
Dec-10-25 04:01PM	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (GlobeNewswire)
Nov-12-25 08:09AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +7.39%
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-06-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 02:40AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -26.09%
Oct-30-25 04:31PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Oct-18-25 03:00AM	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 (GlobeNewswire)
Oct-14-25 08:00AM	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium (GlobeNewswire)
Sep-22-25 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 (GlobeNewswire)
08:00AM	Loading…
Sep-16-25 08:00AM	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +9.61%
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks) -6.33%
Aug-05-25 08:11AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 08:00AM	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress (GlobeNewswire)
Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-24 08:50AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August (GlobeNewswire) +7.13%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +9.17%
Jun-30-24 10:13AM	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-01-24 10:00AM	SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 (GlobeNewswire)
May-30-24 08:00AM	Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-23-24 05:05PM	Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting (GlobeNewswire) -7.96% +8.80%
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +7.89%
May-09-24 08:00AM	Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 01:52PM	CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CEO & DirectorDr. Yuval Cohen Ph.D.

M.B.A.Mr. Sean F. Moran CPA

Ph.D.Dr. Ian Hodgson B.Sc.

M.S.Mr. G. Scott Goeken J.D.

Vice President of Human ResourcesMs. Christina Bertsch M.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smethurst Dominic	Officer	Jul 27 '26	Proposed Sale	9.20	23,025	211,818		Jul 27 04:06 PM
Kung Winston	Director	Jun 10 '26	Sale	7.91	2,026	16,033	12,140	Jun 11 04:30 PM
Altmeyer Anne	Director	Jun 10 '26	Sale	7.91	2,412	19,088	7,579	Jun 11 04:30 PM
Jenkins John Kenneth	Director	Jun 10 '26	Sale	7.91	4,800	37,986	3,833	Jun 11 04:30 PM
Saxena Nishant C	Chief Business Officer	Jun 03 '26	Buy	7.58	9,000	68,220	75,300	Jun 03 05:36 PM
Saxena Nishant C	Chief Business Officer	Jun 02 '26	Buy	7.33	4,500	32,998	66,300	Jun 03 05:36 PM
Smethurst Dominic	Chief Medical Officer	Mar 02 '26	Sale	8.30	6,097	50,601	89,790	Mar 04 04:30 PM
Smethurst Dominic	Officer	Mar 02 '26	Proposed Sale	8.30	6,097	50,601		Mar 02 04:08 PM
Hodgson Ian	Chief Operating Officer	Feb 17 '26	Sale	7.38	847	6,253	51,080	Feb 18 04:32 PM
Moran Sean F.	Chief Financial Officer	Feb 13 '26	Sale	7.78	4,701	36,588	96,694	Feb 18 04:31 PM
Cohen Yuval	Chief Executive Officer	Feb 13 '26	Sale	7.78	13,871	107,952	174,316	Feb 18 04:30 PM
Cohen Yuval	Officer	Feb 13 '26	Proposed Sale	40.63	20,000	812,600		Feb 13 04:02 PM
Smethurst Dominic	Chief Medical Officer	Feb 03 '26	Sale	8.09	3,285	26,575	95,887	Feb 04 04:25 PM
Hodgson Ian	Chief Operating Officer	Feb 03 '26	Sale	8.09	2,415	19,537	51,927	Feb 04 04:24 PM
Cormorant Asset Management, LP	10% Owner	Dec 11 '25	Sale	11.46	30,029	344,012	2,344,971	Dec 15 04:18 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Option Exercise	4.26	18,660	79,492	156,847	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Option Exercise	4.26	8,973	38,225	147,160	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Sale	17.01	18,660	317,407	138,187	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Sale	17.14	8,973	153,797	138,187	Oct 27 04:23 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Option Exercise	4.26	12,981	55,299	86,294	Oct 27 04:22 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Sale	17.02	12,981	220,937	73,313	Oct 27 04:22 PM
Cohen Yuval	Officer	Oct 24 '25	Proposed Sale	17.01	27,633	469,977		Oct 24 04:18 PM
Moran Sean F.	Officer	Oct 24 '25	Proposed Sale	17.02	12,981	220,922		Oct 24 04:14 PM
Altmeyer Anne	Director	Oct 20 '25	Option Exercise	4.80	1,060	5,088	7,251	Oct 21 04:54 PM
Altmeyer Anne	Director	Oct 20 '25	Sale	20.50	1,060	21,730	6,191	Oct 21 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRBP

Corbus Pharmaceuticals Holdings Inc

Upgrade your Finviz experience